Alumis Inc. (NASDAQ: ALMS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
7.82
-0.12-1.51%
News
Down 1.5% — Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review (defenseworld.net).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.92 | Insider Own | 36.62% | Shs Outstand | 123.43M | Perf Week | -21.01% |
| Market Cap | 965.24M | Forward P/E | - | EPS next Y | -2.82 | Insider Trans | 1.93% | Shs Float | 85.84M | Perf Month | -68.57% |
| Enterprise Value | 495.24M | PEG | - | EPS next Q | -0.73 | Inst Own | - | Short Float | 6.58% | Perf Quarter | -66.07% |
| Income | -243.00M | P/S | 40.22 | EPS this Y | -70.05% | Inst Trans | - | Short Ratio | 4.38 | Perf Half Y | -69.24% |
| Sales | 24.00M | P/B | 2.14 | EPS next Y | 13.66% | ROA | -78.30% | Short Interest | 5.65M | Perf YTD | -19.88% |
| Book/sh | 3.66 | P/C | 1.92 | EPS next 5Y | - | ROE | -102.97% | 52W High | 31.36 -75.06% | Perf Year | 87.98% |
| Cash/sh | 4.07 | P/FCF | - | EPS past 3/5Y | - | ROIC | -93.45% | 52W Low | 3.76 107.98% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 88.23% | Volatility | 7.13% 7.45% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 20.63 | EPS Y/Y TTM | 62.81% | Oper. Margin | -6204.39% | ATR (14) | 1.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.74 | Sales Y/Y TTM | - | Profit Margin | -5933.45% | RSI (14) | 19.47 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.74 | EPS Q/Q | 5.13% | SMA20 | -47.89% | Beta | 1.74 | Target Price | 29.57 |
| Payout | 0.00% | Debt/Eq | 0.12 | Sales Q/Q | -33.33% | SMA50 | -65.03% | Rel Volume | 1.51 | Prev Close | 7.94 |
| Employees | 237 | LT Debt/Eq | 0.11 | Earnings | Nov 12 | SMA200 | -64.90% | Avg Volume | 2.33M | Price | 7.82 |
| IPO Date | Jun 28, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -44.72% -54.49% | Net Debt/EBITDA | 0.06 | Volume | 3,513,573 | Change | -1.51% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-03-26 | Downgrade | Guggenheim | Buy → Neutral | |
| Sep-02-26 | Reiterated | Morgan Stanley | Overweight | $29 |
| Sep-02-26 | Upgrade | HC Wainwright & Co. | Neutral → Buy | $25 → $15 |
| Sep-02-26 | Reiterated | Oppenheimer | Outperform | |
| Sep-01-26 | Reiterated | Robert W. Baird | $27 | |
| May-19-26 | Reiterated | Chardan Capital | Buy | |
| May-15-26 | Reiterated | Morgan Stanley | Overweight | |
| May-15-26 | Reiterated | Wells Fargo | Overweight | |
| May-15-26 | Reiterated | Guggenheim | Buy | |
| May-15-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $25 |
Latest News· Times ET
Sep-15-26
Sep-15-2609:29PM
Sep-14-26
06:41AM
Sep-08-26
Sep-08-2609:30PM
Sep-04-26
Sep-04-2611:48PM
03:07PM
04:00AM
Alumis to Participate in Upcoming September Investor Conferencesglobenewswire.com
Sep-01-26
12:36PM
08:24AM
07:03AM
05:16AM
03:30AM
Aug-14-26
Aug-14-2609:26AM
Aug-13-26
Aug-13-2612:01PM
Company
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 24 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 3 | 3 | 0 | — | |
| Gross Profit | 21 | -3 | 0 | — | |
| Selling, General and Administrative Excl. Other | 92 | 35 | 20 | — | |
| Research and Development | 386 | 266 | 138 | — | |
| Other Operating Expense | -30 | -3 | 0 | — | |
| Operating Income | -427 | -301 | -158 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 175 | 7 | 3 | — | |
| Net Income Before Taxes | -252 | -294 | -155 | — | |
| Income Taxes | -9 | 0 | 0 | — | |
| Consolidated Net Income | -243 | -294 | -155 | — | |
| Net Income From Continuing Operations | -243 | -294 | -155 | — | |
| Net Income | -243 | -294 | -155 | — | |
| EPS (Recurring) | -2.32 | -10.38 | -2.99 | — | |
| EPS (Basic, Before Extraordinaries) | -2.32 | -10.38 | -2.99 | — | |
| EPS (Diluted) | -2.32 | -10.38 | -2.99 | — | |
| EBITDA | -248 | -291 | -154 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | 345.67 | — | — | — | |
| Gross Margin | 87.50 | — | — | — | |
| Operating Margin | -1,779.17 | — | — | — | |
| Net Margin | -1,012.50 | — | — | — | |
| Shares Outstanding | 850 | 28 | 52 | — | |
| Market Capitalization | 8,296 | 220 | — | — | |
| Operating Lease Expense | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Sep 08 '26 | Sale | 10.55 | 96,131 | 1,014,028 | 2,025,493 | Sep 09 |
| AKKARAJU SRINIVAS | Director | Sep 08 '26 | Buy | 10.63 | 546,581 | 5,808,571 | 4,937,026 | Sep 09 |
| AKKARAJU SRINIVAS | Director | Sep 04 '26 | Buy | 11.17 | 440,140 | 4,917,684 | 4,711,801 | Sep 09 |
| Schroer John R. | Chief Financial Officer | Aug 03 '26 | Sale | 26.37 | 3,282 | 86,546 | 24,718 | Aug 05 |
| Goldstein David M | Chief Scientific Officer | Aug 03 '26 | Sale | 26.37 | 2,596 | 68,457 | 30,970 | Aug 05 |
| Drappa Jorn | Chief Medical Officer | Aug 03 '26 | Sale | 26.37 | 2,447 | 64,527 | 56,892 | Aug 05 |
| Pangali Sanam | Chief Legal Officer | Aug 03 '26 | Sale | 26.37 | 1,364 | 35,969 | 9,747 | Aug 05 |
| Bradley Mark Christopher | Chief Development Officer | Aug 03 '26 | Sale | 26.37 | 2,572 | 67,824 | 48,533 | Aug 05 |
| Hardiman Roy C. | Chief Business & Strategy Ofcr | Aug 03 '26 | Sale | 26.37 | 2,692 | 70,988 | 207,746 | Aug 05 |
| Pangali Sanam | Chief Legal Officer | Jul 06 '26 | Sale | 28.00 | 5,000 | 140,000 | 11,111 | Jul 08 |
| Pangali Sanam | Chief Legal Officer | Jul 06 '26 | Option Exercise | 5.06 | 5,000 | 25,300 | 16,111 | Jul 08 |
| Drappa Jorn | Chief Medical Officer | May 22 '26 | Option Exercise | 6.65 | 26,852 | 178,649 | 59,339 | May 27 |
| AKKARAJU SRINIVAS | Director | Jan 09 '26 | Buy | 17.00 | 588,235 | 9,999,995 | 1,853,488 | Jan 13 |
| Foresite Labs, LLC | 10% Owner | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 |
| Foresite Capital Management VI LLC | 10% Owner | Jan 08 '26 | Buy | 17.00 | 411,764 | 6,999,988 | 5,702,536 | Jan 12 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.